<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01258686</url>
  </required_header>
  <id_info>
    <org_study_id>BK SIL-C-301</org_study_id>
    <nct_id>NCT01258686</nct_id>
  </id_info>
  <brief_title>Clinical Study With Silymarin in the Patients With Chronic Hepatitis C Infection Who Failed Conventional Antiviral Therapy</brief_title>
  <official_title>A Double-blind Phase III Study With Silymarin in the Patients Infected With HCV Who Failed Conventional Antiviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bukwang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bukwang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness of silymarin 700 mg thrice daily&#xD;
      and assess the safety in patients with hepatitis C virus infection compared to a placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patient with serum ALT less than or equal to 40 IU/L or achieves at least 50% decline to less than 60 IU/L</measure>
    <time_frame>at week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the change from baseline in ALT and HCV RNA (log10)</measure>
    <time_frame>36 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>silymarin, treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Silymarin</intervention_name>
    <description>700mg thrice daily</description>
    <arm_group_label>silymarin, treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 700mg thrice daily</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age at least 18 years at screening.&#xD;
&#xD;
          2. Serum HCV RNA above quantifiable level of detection after the end of previous therapy.&#xD;
&#xD;
          3. ALT &gt; 60 IU/L (i.e., approximately 1.5 X upper limit of normal) obtained during the&#xD;
             screening period.&#xD;
&#xD;
          4. Previous treatment with any interferon-based therapy but 1) without sustained&#xD;
             virological response or 2) HCV RNA detected at the end of the treatment or 3) HCV RNA&#xD;
             undetected during the treatment and detected after or 4) have partial response(HCV RNA&#xD;
             &lt; 2log10 but is not eradicated) or 5) have no response or 6) discontinuation due to&#xD;
             side effect&#xD;
&#xD;
          5. Negative urine pregnancy test (for women of childbearing potential). Females of&#xD;
             childbearing potential must be using effective contraception during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. ALT ≥ 10*ULN(Upper Limit of Normal) at the screening&#xD;
&#xD;
          2. Use of silymarin or other milk thistle preparations within 30 days prior to screening.&#xD;
&#xD;
          3. Use of other antioxidants such as vitamin E, vitamin C, glutathione, alpha-tocopherol,&#xD;
             or non-prescribed complementary alternative medications (including dietary&#xD;
             supplements, megadose vitamins, herbal preparations, and special teas) within 30 days&#xD;
             prior to screening. A multivitamin at standard doses will be allowed.&#xD;
&#xD;
          4. Use of silymarin or other antioxidants or non-prescribed complementary alternative&#xD;
             medications (as above) during the screening period or patient unwilling to refrain&#xD;
             from taking these medications through completion of the study.&#xD;
&#xD;
          5. Any antiviral therapy within 6 months prior to screening visit.&#xD;
&#xD;
          6. Known allergy/sensitivity to milk thistle or its preparations.&#xD;
&#xD;
          7. Evidence of poorly-controlled diabetes (defined as HbA1c &gt; 8% in patients with&#xD;
             diabetes).&#xD;
&#xD;
          8. Use of warfarin, metronidazole or acetaminophen (greater than two grams per day)&#xD;
             within 30 days of screening.&#xD;
&#xD;
          9. Previous Radiology test(Ultrasonography, Computed tomography,Magnetic Resonance&#xD;
             Imaging) or liver biopsy that demonstrated presence of moderate to severe steatosis or&#xD;
             evidence of steatohepatitis.&#xD;
&#xD;
         10. Positive test for anti-HIV or HBsAg within 5 years of screening.&#xD;
&#xD;
         11. Average alcohol consumption of more than one drink or equivalent (&gt;12 grams) per day&#xD;
             or more than two (2) drinks on any one day over the 30 days prior to screening.&#xD;
             Patients who met either criterion more than 30 days ago must have consumed a monthly&#xD;
             average of 12 grams or less per day of alcohol for at least six months prior to&#xD;
             screening.&#xD;
&#xD;
         12. History of other chronic liver disease, including metabolic diseases, documented by&#xD;
             appropriate test(s).&#xD;
&#xD;
         13. Women with ongoing pregnancy or breast-feeding, or contemplating pregnancy.&#xD;
&#xD;
         14. Serum creatinine level 2.0 mg/dL or greater at screening or CrCl ≤ 60cc/min, or&#xD;
             currently on dialysis. The creatinine clearance (CrCl) will be calculated according to&#xD;
             Cockcroft-Gault.&#xD;
&#xD;
         15. Evidence of drug abuse within 6 months prior to screening or during the screening&#xD;
             period.&#xD;
&#xD;
         16. Evidence of decompensated liver disease defined as any of the following: serum albumin&#xD;
             &lt;3.2 g/dl, total bilirubin &gt; 2.0 mg/dl, or PT/INR &gt; 1.3 times normal at screening, or&#xD;
             history or presence of ascites or encephalopathy, or bleeding from esophageal varices.&#xD;
&#xD;
         17. History or other evidence of severe illness or any other conditions that would make&#xD;
             the patient, in the opinion of the investigator, unsuitable for the study (such as&#xD;
             poorly controlled psychiatric disease, coronary artery disease, or active&#xD;
             gastrointestinal conditions that might interfere with drug absorption).&#xD;
&#xD;
         18. History of immunologically mediated disease (e.g., inflammatory bowel disease,&#xD;
             idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hepatitis,&#xD;
             autoimmune hemolytic anemia, severe psoriasis, rheumatoid arthritis) that could affect&#xD;
             inflammatory biomarkers.&#xD;
&#xD;
         19. History of solid organ or bone marrow transplantation.&#xD;
&#xD;
         20. History of thyroid disease poorly controlled on prescribed medications.&#xD;
&#xD;
         21. Use of oral steroids for more than 14 days within 30 days prior to screening.&#xD;
&#xD;
         22. Participation in a research drug trial within 6 months of enrollment.&#xD;
&#xD;
         23. Inability or unwillingness to provide informed consent or abide by the study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Byung Chul Yoo, MD. PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Byung Chul, Yoo</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <study_first_submitted>December 10, 2010</study_first_submitted>
  <study_first_submitted_qc>December 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2010</study_first_posted>
  <last_update_submitted>November 22, 2013</last_update_submitted>
  <last_update_submitted_qc>November 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Silymarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

